Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by tylerreddickon Sep 27, 2024 7:48pm
233 Views
Post# 36244928

Financing

FinancingSBM "management" has claimed they have been trying to get non-dilutive financing, but we all know that is a fantasy. 

If they are going to do a share issue, it would be nice if they would offer it to existing shareholders, those who have paid the price for standing behind the company all these years. But that is probably a fantasy as well, as Howie will take the easiest route. And if some "fund" or other vulture outfit gets the inside scoop that points to profitability, they will be more than anxious to fill their boots at our expense.

But we need a solid financial backer to get GlycoProtMim to market, because without that, and without Abbvie getting off their keesters, this company is in big trouble. Howie holds a good chunk of our debt, so could take SBM private in a bankruptcy (although I wouldn't want to be the guy trying that play).

Probably the best scenario would be to sell 50% of the net profits from GPM, which would finance a lot of other potential products. Yes, that would cut our potential gain in half, short term, but half of a lot is infinitely better than all of nothing.

For those who have held SBM for years, holding for another year to see where we go is a pretty easy decision, at least for me. I have seen little pizzy stocks like this change people's lives, so don't discount the possibility here. JMO
<< Previous
Bullboard Posts
Next >>